02:53:15 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
BioGaia är verksamma inom bioteknik. Bolaget utvecklar, marknadsför och säljer probiotiska produkter. Produkterna är huvudsakligen baserade på bakterien lactobacillus reuteri som har probiotiska effekter. Idag säljs bolagets produkter runtom den globala marknaden. Forskning och utveckling främjas via bolagets externa nätverk av forskningsinstitutioner och kliniker. Huvudkontoret ligger i Stockholm.

Kalender

2022-10-21 Kvartalsrapport 2022-Q3
2022-07-22 Kvartalsrapport 2022-Q2
2022-05-06 Årsstämma 2022
2022-05-06 Kvartalsrapport 2022-Q1
2022-02-04 Bokslutskommuniké 2021
2021-10-21 Kvartalsrapport 2021-Q3
2021-08-12 Kvartalsrapport 2021-Q2
2021-05-07 Ordinarie utdelning BIOG B 3.41 SEK
2021-05-06 Kvartalsrapport 2021-Q1
2021-05-06 Årsstämma 2021
2021-02-04 Bokslutskommuniké 2020
2020-11-25 Extra Bolagsstämma 2020
2020-10-23 Kvartalsrapport 2020-Q3
2020-08-13 Kvartalsrapport 2020-Q2
2020-05-08 Ordinarie utdelning BIOG B 3.75 SEK
2020-05-07 Årsstämma 2020
2020-05-07 Kvartalsrapport 2020-Q1
2020-02-06 Bokslutskommuniké 2019
2019-10-23 Kvartalsrapport 2019-Q3
2019-05-09 Ordinarie utdelning BIOG B 4.05 SEK
2019-05-09 Bonusutdelning BIOG B 5.95
2019-02-07 Bokslutskommuniké 2018
2018-10-24 Kvartalsrapport 2018-Q3
2018-08-17 Kvartalsrapport 2018-Q2
2018-04-26 Ordinarie utdelning BIOG B 4.31 SEK
2018-04-26 Bonusutdelning BIOG B 4.69
2018-04-25 Årsstämma 2018
2018-04-25 Kvartalsrapport 2018-Q1
2018-02-08 Bokslutskommuniké 2017
2017-10-25 Kvartalsrapport 2017-Q3
2017-08-18 Kvartalsrapport 2017-Q2
2017-05-04 Ordinarie utdelning BIOG B 3.16 SEK
2017-05-04 Bonusutdelning BIOG B 4.34
2017-05-03 Kvartalsrapport 2017-Q1
2017-05-03 Årsstämma 2017
2017-02-10 Bokslutskommuniké 2016
2016-10-25 Kvartalsrapport 2016-Q3
2016-08-17 Kvartalsrapport 2016-Q2
2016-05-11 Ordinarie utdelning BIOG B 3.03 SEK
2016-05-11 Bonusutdelning BIOG B 1.97
2016-05-10 Kvartalsrapport 2016-Q1
2016-05-10 Årsstämma 2016
2016-03-18 Extra Bolagsstämma 2016
2016-02-12 Bokslutskommuniké 2015
2015-10-23 Kvartalsrapport 2015-Q3
2015-08-18 Kvartalsrapport 2015-Q2
2015-05-08 Ordinarie utdelning BIOG B 3.46 SEK
2015-05-08 Bonusutdelning BIOG B 1.54
2015-05-07 Årsstämma 2015
2015-05-07 Kvartalsrapport 2015-Q1
2015-02-12 Bokslutskommuniké 2014
2014-10-22 Kvartalsrapport 2014-Q3
2014-08-20 Kvartalsrapport 2014-Q2
2014-05-07 Bonusutdelning BIOG B 3.65
2014-05-07 Ordinarie utdelning BIOG B 3.35 SEK
2014-05-06 Årsstämma 2014
2014-05-06 Kvartalsrapport 2014-Q1
2014-02-12 Bokslutskommuniké 2013
2013-10-23 Kvartalsrapport 2013-Q3
2013-08-22 Kvartalsrapport 2013-Q2
2013-04-29 Ordinarie utdelning BIOG B 4.15 SEK
2013-04-29 Bonusutdelning BIOG B 5.85
2013-04-26 Årsstämma 2013
2013-04-26 Analytiker möte 2013
2013-04-26 Kvartalsrapport 2013-Q1
2013-02-08 Bokslutskommuniké 2012
2012-10-23 Kvartalsrapport 2012-Q3
2012-10-23 Analytiker möte 2012
2012-08-21 Kvartalsrapport 2012-Q2
2012-05-09 Bonusutdelning BIOG B 2.74
2012-05-09 Ordinarie utdelning BIOG B 1.26 SEK
2012-05-08 Årsstämma 2012
2012-05-08 Kvartalsrapport 2012-Q1
2012-02-10 Bokslutskommuniké 2011
2011-11-17 Kapitalmarknadsdag 2011
2011-10-25 Kvartalsrapport 2011-Q3
2011-05-11 Bonusutdelning BIOG B 1.08
2011-05-11 Ordinarie utdelning BIOG B 0.92 SEK
2011-05-10 Årsstämma 2011
2011-05-10 Kvartalsrapport 2011-Q1
2011-02-11 Bokslutskommuniké 2010
2010-10-27 Kvartalsrapport 2010-Q3
2010-08-17 Kvartalsrapport 2010-Q2
2010-05-07 Bonusutdelning BIOG B 0.6
2010-05-07 Ordinarie utdelning BIOG B 0.90 SEK
2010-05-06 Kvartalsrapport 2010-Q1
2010-02-22 Bokslutskommuniké 2009
2009-10-22 Kvartalsrapport 2009-Q3
2009-08-18 Kvartalsrapport 2009-Q2
2009-04-23 Ordinarie utdelning BIOG B 0.40 SEK
2009-04-22 Årsstämma 1
2009-04-22 Kvartalsrapport 2009-Q1
2021-03-17 22:30:00

As part of BioGaia AB's ambition to grow and develop as an innovative life science company, a separate entity, BioGaia Invest (BGI), has been established. The focus of BGI will be to identify and invest in smaller companies focusing on ground-breaking technologies, services and products that will support the growth of BioGaia. 

To fuel continued strong growth and to stay in the forefront of research and innovation, BioGaia AB has created BioGaia Invest (BGI). A total of SEK150 million has been allocated to BGI to enable investments between SEK 5 to 15 million in exciting new companies focusing on ground-breaking technologies, services and/or products. Sebastian Schröder, BioGaia's EVP Business Development, has been appointed Managing Director of BGI.  

BGI will establish communication and information channels that will help BioGaia benefit from new technologies and innovations through collaboration. The purpose is to create a surrounding ecosystem that will contribute to the growth of BioGaia.

"We strongly believe that BioGaia will benefit from the dynamic environment as well as the expertise in new technologies and innovations that these companies will bring" says Isabelle Ducellier, CEO of BioGaia AB.

BGI has so far made two initial investments in cutting edge companies in their respective fields, Boneprox and Skinome.  

Boneprox is a company that specialises in artificial intelligence in dentistry, with a focus on connecting dental care with healthcare. With Boneprox's patented technology, osteoporosis can, among other things, be detected through dental x-rays. Osteoporosis is a bone disorder characterised by low bone mass causing bone fragility. Early diagnosis is crucial to prevent high disease burden. 

BGI has invested approximately SEK 10.5 million in Boneprox in a directed issue in which the former owner, private equity company Backing Minds, also participates. In connection with the investment, Boneprox and BioGaia Japan are joining forces to detect patients at risk for osteoporosis while providing BioGaia's bone health product, BioGaia Osfortis, to subjects with low bone density. 

Skinome is a company working with microbiome friendly skin care. The Skinome products are developed to strengthen the skin's natural microbiome. 

BGI has invested approximately SEK 11.5 million in Skinome in an issue in which the private equity company Spotchain and existing shareholders also participate. In connection with the investment, BioGaia and Skinome will collaborate in the development of microbiome friendly probiotic skin care products both for Skinome and to be rolled out in BioGaia's international network.

"We look forward to new opportunities when collaborating both with Boneprox and Skinome and are convinced that this will lead to increased growth for BioGaia," says Sebastian Schröder, Managing Director of BGI.  

  

Latest press releases from BioGaia
12.02.2021    MetaboGen has reached new crucial milestone in its development of novel probiotic products
04.02.2021    BioGaia AB - Year-end report 2020
03.02.2021    BioGaia revises dividend policy